Fig. 2: Effects of semaglutide compared to placebo across different obesity classes on exercise function, hierarchical composite endpoint and systemic inflammation.

a,b, There was no evidence of heterogeneity in the effects of semaglutide compared to placebo on the confirmatory secondary endpoints of exercise function assessed by 6MWD (a), the hierarchical composite endpoint (b) or systemic inflammation assessed by CRP levels. Data are point estimates and 95% CIs. Analyses using the intention-to-treat principle employ an F-test (a,c) or Cohran’s Q-test (b) for interaction and a Wald test for treatment effect within BMI subgroups, with 1,000 imputations using Rubin’s rule. Analyses using on-treatment data employ an F-test for interaction and a t-test for treatment effect within BMI subgroups (a,c) or Cohran’s Q-test (b) for interaction and a Wald test for treatment effect within BMI subgroups. P values are two-sided. Other abbreviations as in Fig. 1.